News | Heart Valve Technology | November 02, 2018

Valve Replacement Volume Key to Successful Patient Outcomes

New study finds patient outcomes are best at healthcare facilities that perform high volumes of both surgical and transcatheter aortic valve replacements

Valve Replacement Volume Key to Successful Patient Outcomes

November 2, 2018 — Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to adopt a newer, less invasive technique, according to a new study, published Oct. 31 in JAMA Cardiology from Weill Cornell Medicine.1 When hospitals have a high caseload of both, they are likely to achieve the best patient outcomes for those who undergo the newer procedure.

“You can imagine that hospitals known for valve care are more likely to attract valve patients and adopt TAVR [transcatheter aortic valve replacement] more quickly,” said senior author Art Sedrakyan, M.D., Ph.D., a professor of healthcare policy and research at Weill Cornell Medicine. “And it’s likely that the more experience the hospitals have in performing valve surgery, the better patient outcomes are.”

In the study, the investigators sought to examine the relationship between the number of times hospitals perform the established procedure, called surgical aortic valve replacement (SAVR), and patient outcomes from the less invasive TAVR. TAVR has gained popularity in recent years, as it allows surgeons to deliver a valve replacement using only a catheter. TAVR was first approved in 2011 for high-risk patients who were considered inoperable.

Recently, the Centers for Medicare & Medicaid Services (CMS) set criteria to promote high-quality implementation of TAVR, including the requirement that hospitals perform at least 50 SAVR procedures a year prior to beginning TAVR procedures. Due to scrutiny over the requirements, a Medicare Evidence Development & Coverage Advisory Committee panel took place in July to discuss the issue. While some attendees argued for lowering the requirements, as they are difficult to reach in less populated areas, others posited that hospitals with high SAVR numbers would have lower complication rates for TAVR.

To discern that relationship, the Weill Cornell Medicine team, led by Sedrakyan, analyzed more than 60,000 TAVR procedures performed at hospitals between 2011 and 2015. They ultimately found that high volumes of both procedures was associated with the best outcomes for TAVR.

“It’s important that we evaluate TAVR and SAVR in a conjoined way. That’s what makes this study novel – previous studies have not assessed the effect of SAVR volume,” said first author Jialin Mao, M.D., an instructor in healthcare policy and research at Weill Cornell Medicine.

When researchers looked at patient mortality rates 30 days and then one year after undergoing TAVR, they found that patients treated at hospitals with high SAVR volume and high TAVR volume had the lowest mortality. “Patients need to know that getting care at institutions with the highest volume of aortic valve interventional care is most beneficial to them,” Sedrakyan said.

The findings suggest that federal requirements determining hospital eligibility for Medicare and Medicaid reimbursement for TAVR procedures are appropriate and could even be more restrictive.

“Current restrictions need to be maintained and made even stronger,” Sedrakyan said. “We don’t believe the time is right for widespread access to these technologies at the expense of patient safety.”

For more information: www.jamanetwork.com/journals/jamacardiology

Reference

1. Mao J., Redberg R.F., Carroll J.D., et al. Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JAMA Cardiology, published online Oct. 31, 2018. doi:10.1001/jamacardio.2018.3562

Related TAVR Content

Higher Volume of TAVR Boosts Key In-Hospital Outcomes

VIDEO: Impact of TAVR Procedural Volume on Patient Outcomes at ACC.16

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init